Maxim Group set a $1.00 price target on Biopharmx (NYSEAMERICAN:BPMX) in a report released on Monday morning, TipRanks reports. The brokerage currently has a buy rating on the biotechnology company’s stock.
Shares of BPMX remained flat at $$0.38 during midday trading on Monday. 195,100 shares of the company’s stock traded hands, compared to its average volume of 606,573. Biopharmx has a one year low of $0.30 and a one year high of $6.75.
Biopharmx (NYSEAMERICAN:BPMX) last released its quarterly earnings results on Monday, September 9th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.34) by $0.12.
An institutional investor recently bought a new position in Biopharmx stock. Nadler Financial Group Inc. bought a new position in Biopharmx Corp (NYSEAMERICAN:BPMX) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 45,000 shares of the biotechnology company’s stock, valued at approximately $27,000. Nadler Financial Group Inc. owned 0.52% of Biopharmx as of its most recent SEC filing.
BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC).
Featured Story: What are the benefits of investing in REITs?
Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with MarketBeat.com's FREE daily email newsletter.